aTyr Pharma is a clinical stage biotechnology company developing therapies for fibrosis and inflammation using tRNA synthetase biology. The company's lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for interstitial lung disease (ILD), specifically pulmonary sarcoidosis and systemic sclerosis-associated ILD. Efzofitimod selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression. The company maintains a partnership with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod in Japan. Its pipeline includes ATYR0101, a fusion protein derived from aspartyl-tRNA synthetase targeting latent TGF-β Binding Protein-1 to eliminate activated myofibroblasts. aTyr Pharma utilizes a proprietary discovery platform based on domains from all 20 tRNA synthetases to identify new therapeutic intervention points in signaling pathways related to immunology and fibrosis.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage atyrpharma.com
Sector Healthcare IR page investors.atyrpharma.com
Tags
fibrosis, inflammation, interstitial lung disease, pulmonary sarcoidosis, systemic sclerosis, trna synthetase, biologic immunomodulator, myofibroblast, neuropilin-2, clinical stage, efzofitimod, ATYR0101, Kyorin Pharmaceutical Co. Ltd., EFZO-FIT, EFZO-CONNECT, KRP-R120
Press page —

Metrics

Valuation  
Market cap $ 761.034K
Market cap (USD) $ 761.034K
P/E -0.04
PEG —
P/BV 0.02
P/S 4.01
P/OCF -0.02
P/FCF -0.02
Dividend yield —
Turnover / mcap —
Returns  
ROE -107.8%
ROI -130.0%
ROIC -102.1%
Profit margin -39,009.5%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 9
Quality score -62.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 190K 235K 353K 10.386M — 10.455M 422K — — — — —
Net profit -74.118M -64.023M -50.389M -45.338M -33.768M -16.224M -23.603M -34.515M -48.207M -57.855M -47.973M -24.35M
Free cash flow -62.063M -69.184M -37.436M -43.527M -33.267M -15.503M -20.092M -31.657M -43.676M -53.461M -37.461M -23.073M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 0.78 3.62 1.41 2.19 7.47 3.88 4.17 0.5 3.5 2.15 9.83 —
Price performance 12m -0.78 1.57 -0.36 -0.71 0.93 -0.07 7.41 -0.86 0.63 -0.78 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) 339,000 5.01M 7.77M 8.74M — — — — — —
Borrowings, non-current (USD) 9.2M 14.7M 8.26M — — — — — — —
Lease liabilities (USD) — — 3.5M 2.99M 2.24M 1.38M 11.5M 15.1M 13.3M 12M
Cash and deposits (USD) 38.4M 21.1M 23M 9.21M 17M 2.34M 9.98M 22.5M 11.1M 10.7M
Right-of-use assets (USD) — — 3.5M 2.82M 2.08M 1.27M 7.25M 6.73M 5.82M 5.52M
Net debt (borrowings + leases - cash) (USD) -28.9M -1.36M -6.93M 2.52M — — — — — —
Cash flow detail
Operating cash flow (USD) -52.9M -42.4M -31.1M -20M -15.3M -33.1M -41.9M -33.2M -69.1M -62M
Purchases of property, plant and equipment (USD) -600,000 -1.31M -594,000 -79,000 -202,000 -192,000 -1.64M -4.22M -65,000 -77,000
Change in payables (cash effect) (USD) -932,000 -2.49M -2.06M 162,000 1.76M 47,000 6.74M 3.26M -1.34M -33,000
Interest paid (cash effect) (USD) -225,000 -1M -1.7M -1.12M -308,000 0.00 -54,000 -172,000 -137,000 -94,000
Share-based compensation (USD) 5.03M 6.78M 3.43M 1.78M 1.47M 1.61M 2.15M 2.6M 2.99M 5M
Free cash flow (OCF - PPE - intangibles) (USD) -53.5M -43.7M -31.7M -20.1M -15.5M -33.3M -43.5M -37.4M -69.2M -62.1M
Income detail
Research and development expense (USD) 42.8M 30.1M 20.4M 14M 17.3M 23.3M 42.8M 42.3M 54.4M 60.2M
↳ 5y CAGR +8.1% -3.5% -12.9% -11.5% +7.3% +15.7% +31.1% +28.3%
Total comprehensive income (USD) -57.8M -48.3M -34.5M -23.7M -16.2M -34M -45.5M -50M -64M -74.1M
Comprehensive income to owners (USD) -57.8M -48.3M -34.5M -23.6M -16.2M -34M -45.5M -50M -64M -74.1M
Reported Mar 16, 2017 Mar 20, 2018 May 14, 2019 Mar 26, 2020 Mar 24, 2021 Mar 14, 2023 Mar 14, 2023 Mar 14, 2024 Mar 13, 2025 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

aTyr Pharma, Inc. — Other Events Bull 0 Bear 0 Routine

Other Events.

As previously disclosed, on December 4, 2025, aTyr Pharma, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days preceding the date of the Notice, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). On June 3, 2026, the Company received a letter from the Staff (the “Letter”) notifying the Company that the Company is eligible for an additional 180-day period, or until November 30, 2026, to regain compliance, based on the Staff’s determination of the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement. The Notice and the Letter had no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market.

aTyr Pharma, Inc. — Other Events Bull 0 Bear 9 Financing

Other Events.

On November 6, 2026, aTyr Pharma, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) related to the sale of the Company’s common stock, par value $0.001 per share (the “Common Stock”) with the Securities and Exchange Commission (the “SEC”) pursuant to which the Company may offer and sell Common Stock having an aggregate offering price of up to $79,994,251 from time to time under the Company’s Open Market Sale AgreementSM, dated April 22, 2022, as amended December 23, 2024 (the “Sales Agreement”), by and between the Company and Jefferies LLC. The Prospectus Supplement was filed under the Company’s shelf registration statement on Form S-3 (File No. 333-289360), which was initially filed with the SEC on August 7, 2025, and which was declared effective on August 18, 2025. A copy of the legal opinion as to the legality of the $79,994,251 of shares of Common Stock issuable under the Sales Agreement and covered by the Prospectus Supplement is filed as Exhibit 5.1 attached hereto.

Reached alignment with FDA on proposed Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint; study-related activities initiated.

Company to prioritize strategic partnerships to advance Phase 3 study of efzofitimod in pulmonary sarcoidosis.

Ended the third quarter 2026 with $50.3 million in cash, cash equivalents, restricted cash and investments; cash runway into late 2028 based on current operational plans.

SAN DIEGO – November 5, 2026 – aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2026 results and provided a corporate update.

“During the last quarter we reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of our lead therapeutic candidate, efzofitimod, in pulmonary sarcoidosis patients with restrictive lung disease, a major form of interstitial lung disease (ILD) with a high unmet medical need,” said Sanjay S.

Prompts

aTyr Pharma, Inc. (ticker ATYR), listed in United States.

Company History

Date Change Detail
— Former tickers LIFE